Published in AIDS Weekly, September 15th, 2003
Net sales were $10,820,960 and were entirely generated from its healthcare services subsidiary. The company's BioBalance subsidiary is a developmental stage specialty pharmaceutical company which did not generate revenues during this period.
For the second quarter, the company recorded a net loss of $689,088 or $0.03 per share. This compares to a loss of $338,475 for the year-ago period. The loss is due primarily to research-related expenses within the BioBalance subsidiary for development and testing of its proprietary biotherapeutic agent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.